Adipose-derived stromal cells: Their identity and uses in clinical trials, an update

Table 3 Clincial trials using stromal vascular fraction

Clinical trials with SVF	Design	Results	Ref
Traumatic calvaria defect	Autologous SVF + fibrin glue: case report	Success	{Lendeckel, 2004 #483}
Breast reconstruction after lumpectomy	Autologous fat + autologous SVF. No arm control	Cysts and Microcalcifications (4/70 patients)	{Yoshimura, 2008 #481} {Yoshimura, 2008 #481}
	Autologous fat + autologous SVF, phase IV		NCT00616135*
Lipodystrophy I	Autologous SVF + fat	recruiting	NCT00715546*
	Phase I
Non revascularizable myocardium	Autologous SVF	ongoing	NCT00426868*
	Injection into the left ventricle
Treatment of Pts With ST-Elevation Myocardial Infarction	Autologous SVF, Phase I	Ongoing	NCT00442806*
	Injection into the left ventricle
	Autologous SVF, 2 doses against placebo, Phase II, III, Intracoronary injection	Not yet open	NCT01216995*
Diabetes I	“Activated” autologous SVF, phase I/II	recruiting	NCT00703599*
	iv administration
Diabetes II	“Activated” autologous SVF, phase I/II	recruiting	NCT00703612*
Liver cirrhosis	Autologous SVF	Suspended	NCT00913289*
	Intrahepatic arterial administration	suspended	NCT01062750

The clinical trials that are indexed in this table were retrieved using adipose, derived and stem in clinicaltrial and PubMed websites. As discussed in the text, there is some confusion about the use of the term adipose-derived stroma/stem cells. This term should be restricted to cultured mesenchymal stem cells. In fact, it can recover the use of the crude and strongly heterogeneous stroma fraction just after its recovery after fat digestion. The trials listed in this table correspond to the use of such fraction (*identifier on Clinicaltrials website: *http://clinicaltrials.gov/ct2/results?term=adipose+derived+cells). SVF: Stromal vascular fraction.